18 June 2013
Keywords: Merck & Co, BGI, China, Collaboration, Biomarkers, Genomic technology
Article | 15 September 2011
Under a previously-signed statement of intent, US drugs giant Merck & Co (NYSE: MRK), and China-based BGI (formerly the Beijing ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
15 September 2011
14 September 2011
17 June 2013
© 2013 thepharmaletter.com